AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03029715 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil
Description: Narcotics
Study NCT03029715 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: Total intravenous anaesthesia
Study NCT03029715 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Desflurane
Description: Inhalation anaesthesia.
Study NCT00364520 — intervention group
Intervention type: OTHER
Intervention: Shanghai workers
Study NCT04223895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386 Formulation 1
Description: A single oral dose of 1 tablet under fasting conditions for each period
Study NCT04223895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386 Formulation 2
Description: A single oral dose of 1 tablet under fasting conditions for each period
Study NCT04223895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D012, D326 and D337
Description: A single oral dose of 3 tablets(D012, D326 and D337) under fasting conditions for each period
Study NCT05052073 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose load at rest
Description: oral glucose load (75 g) after an 12h overnight fast at rest accompanied by blood sampling and dialysate sampling (adipose tissue and skeletal muscle), and calorimetry (canopy) over three hours.
Study NCT05052073 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose load and exercise
Description: oral glucose load (75 g) after an 12h overnight fast followed by a defined (0.5 W / kg), moderate bicycle exercise i a metabolic chamber
Study NCT02308631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ENDOSCOPICALLY ASSISTED COLOSTOMY WITH COLOPEXY
Description: The endoscope was manipulated until the light approached the pre-set for the use of transillumination site and puncture with the Loop Fixture II gastropexy kit
Study NCT05299775 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: World Health Organization Quality of Life -Brief -Taiwan version (WHOQOL-BREF-Taiwan version)
Description: WHOQOL-BREF-Taiwan version is used to measure the quality of life in HIV infected.~Wang Qi nine kinds of TCM constitution Questionnaire is used to measure the constitution of HIV infected.
Study NCT02245438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir low dose
Study NCT02245438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir high dose
Study NCT02245438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir low dose
Study NCT02245438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir high dose
Study NCT02245438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone-Ethinyl Estradiol
Study NCT03511053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural Steroid Injection with Lavage
Description: All participants will receive a saline lavage prior to the epidural steroid injection.
Study NCT04221763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: His-bundle pacing.
Description: Cardiac resynchronisation therapy can be achieved using biventricular pacing involving placement of three leads into the right atrium, right ventricle and coronary sinus (epicardial left ventricle). Alternatively the third lead may be placed at the bundle of His or left ventricular septum to pace the left bundle directly.
Study NCT00626704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 655
Description: AMG 655 is an investigational, fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5).
Study NCT00626704 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive dummy AMG 655 (to maintain blind)
Study NCT00626704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of Daunorubicin.
Study NCT00626704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of Daunorubicin.
Study NCT02435108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: crizotinib 250mg bid daily
Study NCT01825291 — intervention group
Intervention type: PROCEDURE
Intervention: CPAP treatment
Study NCT02715375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CREON2000A
Study NCT02715375 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CREON2000A
Study NCT02688491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: The investigators randomly assign assay-defined high risk patients of stageIII ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation.
Study NCT02553265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa Low-Dose
Description: 300 mg/day
Study NCT02553265 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo containing an inert substance, in capsule form that does not contain an active drug ingredient.
Study NCT02553265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbidopa High-Dose
Description: 600 mg/day
Study NCT01529177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin / clomid / hCG
Description: Metformin 1000 mg daily for a week then twice daily for 2 weeks then 3 tomes daily for 6 months.
Study NCT01529177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate / hCG
Description: Clomiphene citrate 50 mg daily for one month, then twice daily for 2 months then 3 times per day for 3 months.
Study NCT02485990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Study NCT02485990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Study NCT03874663 — intervention group
Intervention type: DEVICE
Intervention: Directly assisted oral HIV self-testing (HIVST)
Description: 1. To determine the ability of participants with unknown HIV status to correctly perform oral HIVST;~2. To compare the results of the oral HIVST with confirmatory rapid finger prick HIV test.~3. To explore participants attitudes and preferences towards oral HIVST.~4. To explore the feasibility, acceptability and appropriateness of using a mobile photo verification app to verify HIV self-testing results.
Study NCT04271085 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: No intervention involved
Study NCT00941161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin/glimepiride combination
Description: long acting metformin/glimepiride 1g/2mg
Study NCT00941161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: long acting metformin 1g once a day with fasting glucose 130-199mg/dL or long actin metformin 1g twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL
Study NCT00941161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: glimepiride 2mg once a day with fasting glucose 130-199mg/dL, or glimepiride 2mg twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL
Study NCT03294226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AuraGain
Description: After anesthetic induction without neuromuscular blocking agent, AuraGain is inserted.
Study NCT03294226 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel
Description: After anesthetic induction without neuromuscular blocking agent, I-gel is inserted.
Study NCT01998620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ademetionine 2
Description: Ademetionine 1000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 500mg po bid with general antiviral treatment for 8 weeks
Study NCT01998620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ademetionine 1
Description: Ademetionine 2000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
Study NCT01998620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ademetionine 3
Description: no treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
Study NCT01651104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted Trivalent Influenza Virus Vaccine (aTIV)
Description: A single 0.5 mL dose of study vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm.
Study NCT02794818 — intervention group
Intervention type: BEHAVIORAL
Intervention: Produce boxes with nutritional education
Description: CSA produce boxes prescribed to study participants with free online nutritional education included
Study NCT00404820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg solution
Description: Zoledronic acid was supplied as a concentrate of 5.33 mg zoledronic acid monohydrate in a 100 ml solution. 5.33 mg zoledronic acid monohydrate equals 5 mg zoledronic acid.
Study NCT00404820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate 70 mg tablets
Description: Patients received an alendronate 70 mg tablet once weekly with 200 ml of tap water in the morning on an empty stomach at least 30 minutes before the first meal.
Study NCT00404820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium/Vitamin D
Description: Combined elemental calcium / vitamin D chewable tablets. Participants took 2 tablets a day, for a daily dose of calcium 1200 mg/vitamin D 800 IU.
Study NCT00404820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium/Vitamin D
Description: Combined elemental calcium / vitamin D chewable tablets. Participants took 2 tablets a day, for a daily dose of calcium 1200 mg/vitamin D 800 IU.
Study NCT04533282 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples.
Description: Peripheral blood samples (TEMPUS(TM) whole blood samples, EDTA plasma and heparin plasma, total volume 40ml) taken during (1) initial hospitalisation and (2) three month follow-up visit after hospital stay (follow-up samples are not taken from coronary CT healthy control patients).
Study NCT04533282 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of right atrial appendage tissue sample.
Description: Collection of the clinically insignificant small piece of heart's right atrial appendage tissue during either standard cannulation of the right atrium for the installation of the heart-lung machine in the beginning of the operation or additionally for routine surgical protocol.
Study NCT04533282 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Health Survey, Clinical symptom scaling
Description: Patients in the study CABG and AVR cohorts are invited to both pre- and postoperative (3-month time-point), and in the case of PCI cohort only to postoperative, appointments led by experienced clinical cardiologists. The appointments will include clinical anamnesis, status and assessment of morbidity level with combined use of Canadian Cardiovascular Society grading of Angina Pectoris (CCS), New York Heart Association Classification for Heart Failure (NYHA) classification systems and Short Form 36 (SF36) Health Survey. The CT imaging control cohort is not invited to these appointments.
Study NCT04533282 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiography (TTE)
Description: In order to acquire comprehensive insight into the patients' functional heart status, all appointments are supplemented with echocardiographic evaluation for both functional as well as structural parameters. Detailed echocardiographic analysis criteria for the IHD-EPITRAN study are prespecified in the research plan.
Study NCT04968041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program
Description: The intervention using strategies from motivational interviewing and cognitive behavioral therapy to promote motivation and adherence to ketogenic nutrition in older adults at high risk for Alzheimer's disease. The program is a 6-week, group program led by a psychologist and nutrition expert.
Study NCT03712748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginal Exposure therapy
Description: All participants will complete the same arm, which is four sessions of imaginal exposure across a one month time period. Each session is separated by 1 week.
Study NCT03846570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol-beclomethasone
Description: formoterol (fumarate dihydrate) 12 microg - beclomethasone (dipropionate) 200 microg administered BID, per inhalation using '100/6' Metered Dose Inhaler
Study NCT03846570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (identically package) administered BID
Study NCT01573871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Hydrolyzed infant formula
Description: Experimental hydrolyzed infant formula to be fed ad libitum
Study NCT02456597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocainhydrochlorid
Description: Lidocaine injected through the novel Catheter
Study NCT02456597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline
Description: Isotonic saline injected through the novel Catheter
Study NCT01377025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two tablets in the morning and two in the evening.
Study NCT01377025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg Sorafenib bid until PD if staging after Run-In was PR or CR
Study NCT01377025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg Sorafenib bid until PD if staging after Run-In was SD
Study NCT00575536 — intervention group
Intervention type: PROCEDURE
Intervention: Rhizotomy for children with spasticity
Description: Optical Stimulation versus electrical stimulation in children who need Rhizotomy Surgery for spasticity
Study NCT02075242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: experimental group receive Tacrolimus as a main immunosuppressants and assistant is My-rept capsule®(Mycophenolate Mofetil),
Study NCT01851642 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw.
Description: At each study visit, participants will have an intravenous catheter (IV) placed in one of their veins and blood will be drawn from the IV for study testing.
Study NCT02075242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: control group receive same immunosuppressants except for My-rept capsule®(Mycophenolate Mofetil- investigational product
Study NCT02075242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: control group receive same immunosuppressants except for My-rept capsule®(Mycophenolate Mofetil- investigational product
Study NCT00979706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAART
Description: Patients assigned to this arm will receive Trizivir and kaletra. After the first 9 months of HAART, all patients will stop HAART until HIV viral load in plasma became detectable (>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months.~All patients will be followed-up during 1 year.
Study NCT00979706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAART + Immunotherapy
Description: Patients assigned to this arm will receive Trizivir + Kaletra + cyclosporin A during the first two months. This group also will receive GM-CSF plus pegylated-interferon-alpha until HIV viral load in plasma became detectable (>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months. At this moment they will stop HAART.~All patients will be followed-up during 1 year.
Study NCT02679014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: With the exception of the mornings of Days 7 and 21, placebo capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, placebo will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
Study NCT02679014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5459072
Description: With the exception of the mornings of Days 7 and 21, RO5459072 capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, RO5459072 will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
Study NCT00299052 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Grafton DBM
Description: Grafton DBM will be mixed with bone reamings obtained during tibia IMN and place at the fracture site
Study NCT00299052 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reamings
Description: Bone reamings obtained during tibia IMN will be placed at the fracture site
Study NCT03339388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced Lithotripsy System
Description: Stone treatment with the Enhanced Lithotripsy System
Study NCT00161187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: The total CD3+ cell dose target is 1.8 x 108 CD3+ cells/kg +/- 1.0 x 108 CD3+ cells/kg. Up to 6 cycles.
Study NCT01210807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One-Piece Tecnis Multifocal IOL
Description: One-piece Tecnis Multifocal IOL, Model ZMB00, implanted lens.
Study NCT01210807 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: One-Piece Tecnis monofocal IOL, Model ZCB00
Description: Control lens: One-Piece Tecnis monofocal IOL, Model, ZCB00, implanted lens.
Study NCT00516048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10mcg, twice a day
Study NCT00639691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: sc
Study NCT04680728 — intervention group
Intervention type: OTHER
Intervention: collection of biological parameters
Description: haemoglobin, haematocrit, sodium, chloraemia, total protein, albumin, L-lactate, pro-BNP, creatinine, uremia, AST, ALT, GGT, ALP, bilirubin, prothrombin time, urinary test if available.
Study NCT04680728 — intervention group
Intervention type: OTHER
Intervention: collection of echographic parameters
Description: echocardiography (FEVG, subaortic ITV before and after LJP, cardiac index, MAPSE, mitral flow doppler, RVFAC, FEVD, STDVD, VD/VG ratio, TAPSE, tricuspid S wave, IT with PAPs, tricuspid flow doppler), Doppler of suprahepatic veins (S wave, D wave, S/D ratio), renal doppler (VII, RRI, aspect of venous flow in cortical and hilar), femoral venous doppler, doppler of the portal trunk, diameter of the VCI.
Study NCT04680728 — intervention group
Intervention type: OTHER
Intervention: collection of clinical parameters
Description: eason for hospitalisation, co-morbidities, IGS2 score, SOFA, haemodynamic signs (BP, HR, CVP), sinus rhythm or not, temperature, diuresis, weight, input-output assessment, use of dialysis, ventilatory parameters (intubation, mode, FiO2(%), Vt, FR, PEEP, plateau pressure, driving pressure), state of shock (sepsis, postoperative, haemorrhagic, cardiogenic), transfusion (type, number), catecholamines (type, dose, duration), diuretics and dose, clinical criteria of venous congestion (jugular turgidity, hepato-jugular reflux, hepatosplenomegaly, pitting oedemas of the lower limbs, hepatalgia), neurological evaluation (Glasgow Coma Scale, CAM-ICU), time to resume enteral feeding and bowel movements, weight.
Study NCT02556502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-Florbetaben PET
Study NCT01188200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental nutritional formula #M979
Description: One two hundred and forty mL serving at test time, taken orally
Study NCT01188200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard food
Description: Standard meal prior to test time
Study NCT03439436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xylo+dex nasal spray (0.1 mg+5 mg/dose)
Description: Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
Study NCT03439436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasic
Description: Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
Study NCT02665169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise
Description: Supervised physical exercises in Taiji and weight training. Free use and access into municipal recreation and training facilities for one year.
Study NCT02665169 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health counselling
Description: Health counselling, fall prevention strategies at home, information concerning municipal recreational services available.
Study NCT02665169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health counselling
Description: Health counselling, fall prevention strategies at home, information concerning municipal recreational services available.
Study NCT01775332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: A brochure and access to a website including videos that contain detailed information about pituitary disorders will serve as the educational intervention.